Patients who underwent sublobar resection and those who underwent more invasive lobectomy for early-stage non–small cell lung cancer (NSCLC) showed similar overall and disease-free survival outcomes in a recent study.
The traditional treatment for early-stage non-small cell lung cancer is a lobectomy, where a surgeon eradicates cancerous tissue by removing an entire lung lobe.
During a highly-anticipated “Cancer Breakthroughs” session at ASTRO2022, incoming ASTRO President Jeff Michalski, MD, MBA, FASTRO, moderated the presentation of significant findings from representatives of ASCO and AAPM.